CLEC4C
ENSG00000198178
Target class
Membrane receptor
Chromosome
12
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- CLEC4C
- Gene name
- C-type lectin domain family 4 member C
- Gene symbol
- CLEC4C
- Protein name
- C-type lectin domain family 4 member C (Blood dendritic cell antigen 2) (BDCA-2) (C-type lectin superfamily member 7) (Dendritic lectin) (CD antigen CD303)
- HECL
- DLEC
- BDCA2
- CD303
- CLECSF11
- CLECSF7
- Gene biotype
- Protein coding
- Gene family
- CD molecules|C-type lectin domain containing
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 1.13
- Tissue specificity (Gini)
- 0.949
- Tissue specificity (tau)
- 0.983
- KEGG gene identifiers
- hsa:170482
- Protein interaction confidence
- 0.8492
- Protein interaction partners
- 10
- R-HSA-5621480
- R-HSA-6798695
- End position
- 7751620
- Start position
- 7724646
- Chromosome
- 12
- Strand
- Reverse
- Cell membrane
- Single-pass type II membrane protein .
- PubMed 11748283
- PubMed 21880719
- Tissue specificity (tau)
- 0.982802
- Expression inequality (Gini)
- 0.949074
Expression in transcripts per million
- Testis
- 1.13
- Whole Blood
- 0.52
- Cells - EBV-transformed lymphocytes
- 0.27
- Spleen
- 0.17
- Lung
- 0.04
Expression in transcripts per million
- Testis1.13
- Whole Blood0.52
- Cells - EBV-transformed lymphocytes0.27
- Spleen0.17
- Lung0.04
- Bladder0.02
- Kidney - Medulla0.01
- Fallopian Tube0
- Brain - Cerebellum0
- Breast - Mammary Tissue0
- Esophagus - Gastroesophageal Junction0
- Uterus0
- Heart - Left Ventricle0
- Brain - Hippocampus0
- Pituitary0
- Nerve - Tibial0
- Prostate0
- Thyroid0
- Brain - Cortex0
- Brain - Anterior cingulate cortex (BA24)0
- Esophagus - Mucosa0
- Muscle - Skeletal0
- Artery - Coronary0
- Kidney - Cortex0
- Adipose - Visceral (Omentum)0
And 29 more, listed on the interactive page.
- GO:0005886
- GO:0030667
- GO:0070821
- GO:0101003
Molecular functions
- GO:0005515
Related records
Trials (9)
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
- A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
- A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
- A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
- A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
- An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
- Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.
- Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
- Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Drugs (1)
- Litifilimab C-type lectin domain family 4 member C inhibitor